

Prior Authorization Criteria
Avastin (bevacizumab) and bevacizumab biosimilars

All requests for Avastin (bevacizumab) and bevacizumab biosimilars require a prior authorization and will be screened for medical necessity and appropriateness using the criteria listed below.

For all oncology-related requests for Avastin® (bevacizumab) and bevacizumab biosimilars, please refer to the Oncology Medications, IV/Injectable policy (CP-206.133-MD-PA).

For all ophthalmic-related requests for Avastin® (bevacizumab) and bevacizumab biosimilars, coverage may be provided for a FDA approved, compendia supported, or peer reviewed medical literature supported diagnosis

- **Duration of Approval:**
 - Retinopathy of Prematurity: 1 month
 - All other ophthalmic indications: 12 months

Coverage may be provided for any non-FDA labeled indication if it is determined that the use is a medically accepted indication supported by nationally recognized pharmacy compendia or peer-reviewed medical literature for treatment of the diagnosis(es) for which it is prescribed. These requests will be reviewed on a case by case basis to determine medical necessity.

When criteria are not met, the request will be forwarded to a Medical Director for review. The physician reviewer must override criteria when, in their professional judgment, the requested medication is medically necessary.

